197 related articles for article (PubMed ID: 15593112)
1. Aristoforin, a novel stable derivative of hyperforin, is a potent anticancer agent.
Gartner M; Müller T; Simon JC; Giannis A; Sleeman JP
Chembiochem; 2005 Jan; 6(1):171-7. PubMed ID: 15593112
[TBL] [Abstract][Full Text] [Related]
2. Hyperforin.
Beerhues L
Phytochemistry; 2006 Oct; 67(20):2201-7. PubMed ID: 16973193
[TBL] [Abstract][Full Text] [Related]
3. Role of hyperforin in the pharmacological activities of St. John's Wort.
Zanoli P
CNS Drug Rev; 2004; 10(3):203-18. PubMed ID: 15492771
[TBL] [Abstract][Full Text] [Related]
4. Instability of St. John's wort (Hypericum perforatum L.) and degradation of hyperforin in aqueous solutions and functional beverage.
Ang CY; Hu L; Heinze TM; Cui Y; Freeman JP; Kozak K; Luo W; Liu FF; Mattia A; DiNovi M
J Agric Food Chem; 2004 Oct; 52(20):6156-64. PubMed ID: 15453681
[TBL] [Abstract][Full Text] [Related]
5. Hyperforin and aristoforin inhibit lymphatic endothelial cell proliferation in vitro and suppress tumor-induced lymphangiogenesis in vivo.
Rothley M; Schmid A; Thiele W; Schacht V; Plaumann D; Gartner M; Yektaoglu A; Bruyère F; Noël A; Giannis A; Sleeman JP
Int J Cancer; 2009 Jul; 125(1):34-42. PubMed ID: 19326439
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis.
Schempp CM; Kirkin V; Simon-Haarhaus B; Kersten A; Kiss J; Termeer CC; Gilb B; Kaufmann T; Borner C; Sleeman JP; Simon JC
Oncogene; 2002 Feb; 21(8):1242-50. PubMed ID: 11850844
[TBL] [Abstract][Full Text] [Related]
7. DNA-protective activities of hyperforin and aristoforin.
Ševčovičová A; Šemeláková M; Plšíková J; Loderer D; Imreová P; Gálová E; Kožurková M; Miadoková E; Fedoročko P
Toxicol In Vitro; 2015 Apr; 29(3):631-7. PubMed ID: 25678043
[TBL] [Abstract][Full Text] [Related]
8. Tetrahydrohyperforin and octahydrohyperforin are two new potent inhibitors of angiogenesis.
Martínez-Poveda B; Verotta L; Bombardelli E; Quesada AR; Medina MA
PLoS One; 2010 Mar; 5(3):e9558. PubMed ID: 20224821
[TBL] [Abstract][Full Text] [Related]
9. Anticancer and Antibacterial Activity of Hyperforin and Its Derivatives.
Pia Schiavone BI; Verotta L; Rosato A; Marilena M; Gibbons S; Bombardelli E; Franchini C; Corbo F
Anticancer Agents Med Chem; 2014; 14(10):1397-1401. PubMed ID: 25173557
[TBL] [Abstract][Full Text] [Related]
10. Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures.
Komoroski BJ; Parise RA; Egorin MJ; Strom SC; Venkataramanan R
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6972-9. PubMed ID: 16203790
[TBL] [Abstract][Full Text] [Related]
11. [Hypericin and hyperforin: bioactive components of St. John's Wort (Hypericum perforatum). Their isolation, analysis and study of physiological effect].
Vacek J; Klejdus B; Kubán V
Ceska Slov Farm; 2007 Apr; 56(2):62-6. PubMed ID: 17619301
[TBL] [Abstract][Full Text] [Related]
12. Hyperforin: To Be or Not to Be an Activator of TRPC(6).
Friedland K; Harteneck C
Rev Physiol Biochem Pharmacol; 2015; 169():1-24. PubMed ID: 26384487
[TBL] [Abstract][Full Text] [Related]
13. Effect of eluent pH on the HPLC-UV analysis of hyperforin from St. John's Wort (Hypericum perforatum L.).
Fourneron JD; Naït-Si Y
Phytochem Anal; 2006; 17(2):71-7. PubMed ID: 16634282
[TBL] [Abstract][Full Text] [Related]
14. Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line.
Tian R; Koyabu N; Morimoto S; Shoyama Y; Ohtani H; Sawada Y
Drug Metab Dispos; 2005 Apr; 33(4):547-54. PubMed ID: 15640377
[TBL] [Abstract][Full Text] [Related]
15. Cellular neurobiology of hyperforin.
Bouron A
Phytother Res; 2024 Feb; 38(2):636-645. PubMed ID: 37963759
[TBL] [Abstract][Full Text] [Related]
16. Hyperforin, a new lead compound against the progression of cancer and leukemia?
Quiney C; Billard C; Salanoubat C; Fourneron JD; Kolb JP
Leukemia; 2006 Sep; 20(9):1519-25. PubMed ID: 16791262
[TBL] [Abstract][Full Text] [Related]
17. NMDA receptor-antagonistic properties of hyperforin, a constituent of St. John's Wort.
Kumar V; Mdzinarishvili A; Kiewert C; Abbruscato T; Bickel U; van der Schyf CJ; Klein J
J Pharmacol Sci; 2006 Sep; 102(1):47-54. PubMed ID: 16936454
[TBL] [Abstract][Full Text] [Related]
18. Hyperforin: more than an antidepressant bioactive compound?
Medina MA; Martínez-Poveda B; Amores-Sánchez MI; Quesada AR
Life Sci; 2006 Jun; 79(2):105-11. PubMed ID: 16438991
[TBL] [Abstract][Full Text] [Related]
19. Simple 2,4-diacylphloroglucinols as classic transient receptor potential-6 activators--identification of a novel pharmacophore.
Leuner K; Heiser JH; Derksen S; Mladenov MI; Fehske CJ; Schubert R; Gollasch M; Schneider G; Harteneck C; Chatterjee SS; Müller WE
Mol Pharmacol; 2010 Mar; 77(3):368-77. PubMed ID: 20008516
[TBL] [Abstract][Full Text] [Related]
20. Antidepressant activity of hyperforin conjugates of the St. John's wort, Hypericum perforatum Linn.: an experimental study.
Muruganandam AV; Bhattacharya SK; Ghosal S
Indian J Exp Biol; 2001 Dec; 39(12):1302-4. PubMed ID: 12018529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
